Nicholas Hoffman & Company LLC. Buys 9,188 Shares of Solventum Corporation $SOLV

Nicholas Hoffman & Company LLC. increased its position in Solventum Corporation (NYSE:SOLV) by 113.3% during the first quarter, HoldingsChannel.com reports. The firm owned 17,294 shares of the company’s stock after acquiring an additional 9,188 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Solventum were worth $1,129,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of SOLV. Assetmark Inc. increased its stake in Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after purchasing an additional 128 shares in the last quarter. Hilltop National Bank lifted its stake in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after buying an additional 129 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after buying an additional 129 shares during the last quarter. CIBC Private Wealth Group LLC grew its holdings in shares of Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after buying an additional 134 shares during the last quarter. Finally, BOKF NA increased its position in shares of Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after acquiring an additional 141 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on SOLV shares. Piper Sandler decreased their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Rothschild & Co Redburn initiated coverage on Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target for the company. KeyCorp upped their price target on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Wedbush initiated coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price objective for the company. Finally, BTIG Research reissued a “buy” rating and issued a $89.00 target price on shares of Solventum in a research report on Wednesday, May 6th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $83.73.

Solventum Trading Down 2.2%

NYSE:SOLV opened at $76.24 on Wednesday. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $88.20. The company has a market cap of $13.20 billion, a PE ratio of 9.34, a price-to-earnings-growth ratio of 1.20 and a beta of 0.66. The company has a 50 day simple moving average of $75.76 and a two-hundred day simple moving average of $74.38.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.13. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.